AbelZeta Pharma Announces Clinical Data Presentation for C-CAR168 at ACR Convergence 2025

Strategic Insights -

AbelZeta Pharma, a global clinical-stage biopharmaceutical company, announced that clinical data from the first-in-human Phase I trial of C-CAR168 in patients with refractory autoimmune diseases will be presented at the American College of Rheumatology (ACR) Convergence 2025. The presentation will highlight the potential of C-CAR168 to simultaneously target autoantibody-producing plasma cells and their B-cell precursors, aiming to achieve "immune reset" in patients with refractory autoimmune diseases.

Key Takeaways:

  • C-CAR168 is an autologous anti-CD20/BCMA bispecific Chimeric Antigen Receptor T-cell (CAR-T) therapy designed to target autoantibody-producing plasma cells and their B-cell precursors.
  • The Phase I trial of C-CAR168 is focusing on patients with refractory autoimmune diseases, aiming to achieve "immune reset" in these patients.
  • The presentation will take place on Tuesday, October 28, 2025, from 10:30 AM - 12:30 PM CT at McCormick Place in Chicago, Illinois.
  • AbelZeta's pipeline is comprised of CAR-T therapies, and the company is advancing research and development in its own GMP facilities at its centers of excellence.
  • The company's focus is on developing innovative and proprietary cell-based therapeutic products to harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases.

Statistics:

  • The Phase I trial of C-CAR168 has enrolled patients with refractory autoimmune diseases.
  • The trial is a first-in-human study, indicating that it is the initial clinical trial of C-CAR168 in human subjects.
  • The ACR Convergence 2025 will draw over 20,000 attendees from around the globe.
  • The Annual Meeting of the American College of Rheumatology (ACR) has grown from 5,000 attendees in 1990 to over 20,000 attendees in 2025.
  • CAR-T therapy is a type of immunotherapy that has gained significant attention in recent years for its potential to treat hematological malignancies and solid tumors.
  • AbelZeta Pharma is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland, and Shanghai, China.
  • The company has a pipeline of CAR-T therapies, including C-CAR168, and is advancing research and development in its own GMP facilities at its centers of excellence.

Sources:

  • [1] AbelZeta Pharma, Inc. (2025). AbelZeta Pharma Announces Clinical Data Presentation for C-CAR168 at ACR Convergence 2025. Retrieved from PRNewswire website.
  • [2] AbelZeta Pharma, Inc. (2025). About AbelZeta Pharma, Inc. Retrieved from AbelZeta Pharma, Inc. website.
  • [3] American College of Rheumatology (2025). ACR Convergence 2025. Retrieved from American College of Rheumatology website.